LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial
AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with the broader market's downturn, which saw a 1.1% drop amid ongoing concerns about international trade, particularly following U.S. tariff policies. Amid these market pressures, the company's collaboration with Daiichi Sankyo was highlighted by the announcement of successful phase 3 trial results for ENHERTU, which positively impacts the oncology sector. Although...